abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 03월 02일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제109회 대한화학회 학술발표회, 총회 및 기기전시회 안내 Development of a New Generation of Drug to Overcome NSCLC Resistance

등록일
2012년 2월 23일 14시 10분 49초
접수번호
1427
발표코드
MEDI-3 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
금 11시 : 00분
발표형식
심포지엄
발표분야
의약화학 - Drugs on the way for successful IND
저자 및
공동저자
서귀현
한미약품(주) 연구센터, Korea
Non-small cell lung cancer (NSCLC) associated with activating epidermal growth factor receptor (EGFR) mutations are initially responsive to EGFR-targeted tyrosine kinase inhibitor (TKI) such as Gefitinib and Erlotinib, but it appeared that most of patients fail to these drugs within one year because of several type of acquired resistance. Among these, the gatekeeper T790M point mutation accounts for about half of all resistance. While multiple clinical trials have studied therapies to overcome T790M resistance together with the development of new EGFR TKIs of pan-Her inhibitors, no therapy or drug being able to change clinical practice for T790M resistance has been developed until now. In this presentation, a novel EGFR TKI will be introduced as a next generation of drug to target acquired resistance of T790M as well as inherent activating EGFR mutations.

상단으로